Climb Bio (CLYM) Net Income towards Common Stockholders (2020 - 2026)
Climb Bio (CLYM) posted Net Income towards Common Stockholders of -$46.1 million for Q1 2026, down 57.73% on a QoQ basis from -$29.2 million in Q4 2025, and down 116.57% year-over-year from $278.0 million in Q1 2025.
Climb Bio (CLYM) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Climb Bio's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$46.1 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 116.57% year-over-year to -$46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.3 million (down 0.81% YoY) and the FY2025 annual result came in at -$71.3 million, up 30.37% from the prior year.
- Net Income towards Common Stockholders was -$46.1 million for Q1 2026 at Climb Bio, down from -$29.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.7 million in Q1 2024 and bottomed at -$57.7 million in Q2 2024.
- A 5-year average of -$18.0 million and a median of -$13.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders surged 89.04% — and 2025, when it tumbled 676.95%.
- Climb Bio's Net Income towards Common Stockholders stood at -$7.8 million in 2022, then plunged by 217.3% to -$24.6 million in 2023, then soared by 64.92% to -$8.6 million in 2024, then slumped by 237.93% to -$29.2 million in 2025, then slumped by 57.73% to -$46.1 million in 2026.
- Business Quant data shows CLYM's Net Income towards Common Stockholders at -$46.1 million in Q1 2026, -$29.2 million in Q4 2025, and -$14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Climb Bio | 877.15 Mn | 877.15 Mn | - | -46.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.05 Mn |
| Dec 31, 2025 | -29.20 Mn |
| Sep 30, 2025 | -14.46 Mn |
| Jun 30, 2025 | -8.54 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -8.64 Mn |
| Sep 30, 2024 | -9.88 Mn |
| Jun 30, 2024 | -57.68 Mn |
| Mar 31, 2024 | -2.74 Mn |
| Dec 31, 2023 | -24.63 Mn |
| Sep 30, 2023 | -5.06 Mn |
| Jun 30, 2023 | -7.84 Mn |
| Mar 31, 2023 | -24.98 Mn |
| Dec 31, 2022 | -7.76 Mn |
| Sep 30, 2022 | -9.68 Mn |
| Jun 30, 2022 | -14.60 Mn |
| Mar 31, 2022 | -13.20 Mn |
| Dec 31, 2021 | -10.55 Mn |
| Sep 30, 2021 | -10.94 Mn |
| Jun 30, 2021 | -10.86 Mn |